Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark
California
94560
United States
Tel: 510-742-3400
Fax: 510-742-3401
Website: http://www.revance.com/
Email: careers@revance.com
303 articles about Revance Therapeutics, Inc.
-
Revance Provides Corporate Update and Anticipated Milestones for 2020
1/9/2020
Revance Therapeutics, Inc., a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, provided a corporate and product pipeline update and shared anticipated milestones for 2020.
-
Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology
12/5/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating Revance’s long-acting neuromodulator product, DaxibotulinumtoxinA
-
Revance Announces Pricing of Public Offering of Common Stock at $17.00 per share.
12/4/2019
Revance Therapeutics, Inc. announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $17.00 per share.
-
Revance Announces Proposed Public Offering of Common Stock - Dec. 3, 2019
12/3/2019
Revance Therapeutics, Inc. announced a proposed underwritten public offering of its common stock.
-
Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics
12/2/2019
Appointment completes build-out of Revance’s commercial leadership team following submission of the Company’s Biologics License Application to the U.S. Food and Drug Administration for DaxibotulinumtoxinA for Injection (DAXI)
-
Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines
11/25/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines.
-
Revance to Participate in the Stifel 2019 Healthcare Conference
11/12/2019
Revance Therapeutics, Inc., a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, announced that the company will participate in the Stifel 2019 Healthcare Conference, in New York, NY.
-
Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference
11/6/2019
Revance Therapeutics, Inc., a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, announced that the company will participate in the Credit Suisse 28th Annual Healthcare Conference, in Scottsdale, AZ.
-
Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update
11/4/2019
Revance Therapeutics, Inc. reported financial results for the quarter ended September 30, 2019, and provided a corporate update.
-
Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery
11/4/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the publication of results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery (PRS), the peer reviewed Journal of the American Society of Plastic Surgeons.
-
Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
11/4/2019
DaxibotulinumtoxinA for Injection (DAXI) has potential to be first long-acting neuromodulator for treatment of this debilitating involuntary muscle movement disorder
-
Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019
10/28/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release third quarter 2019 financial results on Monday, November 4, 2019 after the close of market.
-
Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting
10/23/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced three oral presentations at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting to be held in Chicago, October 24-27, 2019.
-
Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne
10/14/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the appointment of Mark Foley as President and CEO, replacing Dan Browne, who has stepped down due to a misjudgment in handling an employee matter.
-
Revance Earns Great Place to Work® Certification for Second Year
10/2/2019
Revance Therapeutics, Inc. announced the company is certified as a great workplace by the independent analysts at Great Place to Work® for the second consecutive year.
-
Revance to Participate in the 2019 Cantor Global Healthcare Conference
9/25/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York, NY.
-
Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
9/4/2019
Morgan Stanley 17th Annual Global Healthcare Conference, in New York, NY.
-
Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference
8/28/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare Conference, in Boston, MA.
-
Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update
8/5/2019
Conference call and webcast today at 4:30 p.m. ET
-
Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019
7/29/2019
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release second quarter 2019 financial results on Monday, August 5, 2019 after the close of market